Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib With Best Available Therapy in Hydroxyurea-Resistant/Intolerant Patients with Polycythemia Vera
Phase 3 RESPONSE study 5-year follow-up results demonstrate that clinical benefit, including clinicohematologic response and hematocrit control, is durable with long-term ruxolitinib therapy among patients with hydroxyurea-resistant/intolerant polycythemia vera.
Blood (ASH Abstract)
In The News
American Journal of Managed Care
In The Literature
American Journal of Hematology European Journal of Haematology New England Journal of Medicine